• Users Online: 3029
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe News Contacts Login 
REVIEW ARTICLE
Year : 2019  |  Volume : 3  |  Issue : 1  |  Page : 1-6

Usage and safety of direct oral anticoagulants at patients with atrial fibrillation and planned diagnostic procedures, interventions, and surgery


1 Institute for Cardiovascular Prevention and Rehabilitation; School of Dental Medicine, University of Zagreb, Zagreb, Croatia
2 Institute for Cardiovascular Prevention and Rehabilitation, Zagreb; The Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek; University of Applied Health Sciences, Zagreb, Croatia
3 School of Dental Medicine, University of Zagreb; Department of Emergency Medicine, Internal Medicine Clinic, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia

Correspondence Address:
Dr. Marko Mornar Jelavic
Institute for Cardiovascular Prevention and Rehabilitation, Draskoviceva 13, HR-10000, Zagreb
Croatia
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/hm.hm_61_19

Rights and Permissions

Atrial fibrillation (AF) affects about 2% of the population, with the increasing prevalence with age. It is associated with poorer quality of life, effort intolerance, frequent hospitalizations, heart failure, and increased risk of systemic embolization, stroke, and mortality. Warfarin has been the only choice of chronic anticoagulant therapy for over 50 years. Its disadvantages are reflected by interaction with various foods, drugs, and alcohol, while its action is highly dependent on liver function, age, and genetic background. Administration of direct oral anticoagulants (DOACs) to patients with AF and acceptable bleeding risk reduces the risk of systemic thromboembolic complications and stroke; these drugs are superior or at least as effective as warfarin. Their use is safer than warfarin in terms of reduced risk of major bleeding. This is a group of drugs with wide clinical use, except in patients with severely impaired renal and hepatic function. Proper use is a guarantee of the safety of DOACs, which in the future will be even more pronounced with the advent of new antidotes, such as Praxbind.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2132    
    Printed136    
    Emailed0    
    PDF Downloaded238    
    Comments [Add]    
    Cited by others 2    

Recommend this journal